ArticleTrials2021

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial.

Maike H M Wientjes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.